Collaboration as the key to turning around the drug discovery business (Part 11) – The future
The prerequisite to enable the efficiencies of integrated specialization, are secure, trusted collaborative platforms. Mechanisms are required that balance allowing maximum collective contributions, with maximum control of intellectual property ownership. Fortunately, technologies are emerging in this area to allow what was previously impossible, to become routine. Platforms like LinkedIn and Facebook, with rich, flexible privacy and sharing controls, give us insight into the collective efficiencies that are now just within our grasp.
For more context on how and why collaboration is the key to turning around the drug discovery business:
Especially read Part 9: Collaboration as the key to turning around the drug discovery business – Collaborate Better
P.S. Beyond collaboration as a more enlightened approach to science, here are the top 5 practical reasons collaborative scientists rock with CDD: https://www.collaborativedrug.com/buzz/2011/10/17/5-reasons-why-collaborative-scientists-use-cdd/
You can also download the full series “Collaboration as the key to turning around the drug discovery business” by Barry Bunin as a pdf document: